OPTR

PropThink: Lower Dificid Price Doesn’t Resonate With Analysts; OPTR Could Trade Lower

[ACN Newswire] – By David MoskowitzYesterday, Optimer Pharmaceuticals (NASDAQ:OPTR) hosted its Analyst Day, describing a new lower pricing policy with hospitals to spur demand of Dificid. Our negative view of the meeting … moreView todays social media effects on OPTRView the latest stocks trending across Twitter. Click to view dashboard¬†[…]

PropThink: OPTR Fighting Weak Dificid Trends With Price Reduction, Estimates Going Down

[ACN Newswire] – By David MoskowitzOptimer Pharmaceuticals (NASDAQ:OPTR) is hosting its Analyst Day in NYC this morning and is detailing its new strategy, which includes lowering the price for lead growth driver, Dificid, … moreView todays social media effects on OPTRView the latest stocks trending across Twitter. Click to view dashboard¬†[…]